Rep. Thomas H. Kean, Jr. Sells Off Becton, Dickinson and Company (NYSE:BDX) Stock

Posted by Francis Steltz on Jul 4th, 2026

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on June 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Becton, Dickinson and Company stock on May 21st. The trade occurred in the Representative’s “KEAN FAMILY PARTNERSHIP” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Check Point Software Technologies (NASDAQ:CHKP) on 6/1/2026.
Purchased $1,001 – $15,000 in shares of EQT (NYSE:EQT) on 6/1/2026.
Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 5/14/2026.
Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 4/29/2026.
Sold $1,001 – $15,000 in shares of Take-Two Interactive Software (NASDAQ:TTWO) on 4/21/2026.
Sold $1,001 – $15,000 in shares of nVent Electric (NYSE:NVT) on 4/15/2026.
Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 4/14/2026.
Sold $1,001 – $15,000 in shares of First Citizens BancShares (NASDAQ:FCNCA) on 4/14/2026.
Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 3/31/2026.
Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 3/26/2026.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $0.02 during midday trading on Friday, reaching $158.10. The company’s stock had a trading volume of 2,036,087 shares, compared to its average volume of 2,812,766. The business’s fifty day simple moving average is $147.98 and its 200-day simple moving average is $169.33. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a market capitalization of $43.56 billion, a P/E ratio of 40.02, a P/E/G ratio of 11.19 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Empowered Funds LLC grew its position in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the last quarter. United Bank grew its position in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after purchasing an additional 993 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after purchasing an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock worth $765,120 in the last quarter. Company insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus lowered their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, Bank of America decreased their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $181.00.

View Our Latest Research Report on Becton, Dickinson and Company

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.